A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting
GUS: Gadavist Drug Utilization Study
Sponsor: Bayer
A observational or N/A phase clinical study on Contrast Enhancement in Magnetic Resonance Imaging, this trial is completed. The trial is conducted by Bayer and has accumulated 15 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
May 2024 — Jul 2024 [monthly]
Completed
-
Jun 2023 — May 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
May 2023 — Jun 2023 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
▶ Show 10 earlier versions
-
Apr 2023 — May 2023 [monthly]
Recruiting
-
Mar 2023 — Apr 2023 [monthly]
Recruiting
-
Feb 2023 — Mar 2023 [monthly]
Recruiting
-
Jan 2023 — Feb 2023 [monthly]
Recruiting
-
Dec 2022 — Jan 2023 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Nov 2022 — Dec 2022 [monthly]
Not Yet Recruiting
-
Sep 2022 — Nov 2022 [monthly]
Not Yet Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Not Yet Recruiting
-
Jun 2022 — Jul 2022 [monthly]
Not Yet Recruiting
-
May 2022 — Jun 2022 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
For direct contact, visit the study record on ClinicalTrials.gov .